Literature DB >> 2540247

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.

S A Plotkin1, S E Starr, H M Friedman, E Gönczöl, R E Weibel.   

Abstract

To test the protective effect of Towne live attenuated human cytomegalovirus (HCMV) vaccine in normal individuals, we developed a parenteral challenge consisting of a low-passage isolate (Toledo stain) inoculated subcutaneously in graded doses. This challenge virus caused a mild mononucleosis syndrome in seronegative individuals at doses of 10 or 100 pfu. The illness was accompanied by atypical lymphocytosis, raised hepatic enzymes, excretion of HCMV and HCMV-specific immune responses. Naturally seropositive volunteers also developed clinical and laboratory evidence of infection after challenge with 1,000 pfu of Toledo but resisted 10 or 100 pfu. Volunteers who had been vaccinated 1 y earlier also were resistant to disease caused by 10 or 100 pfu of Toledo, although some were asymptomatically infected by the 100 pfu dose. Vaccine-induced immunity to HCMV was as complete as naturally induced immunity when the challenge dose of Toledo was 10 pfu.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540247     DOI: 10.1093/infdis/159.5.860

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  57 in total

1.  Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.

Authors:  Laura Hertel; Vashti G Lacaille; Herbert Strobl; Elizabeth D Mellins; Edward S Mocarski
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  RASCAL is a new human cytomegalovirus-encoded protein that localizes to the nuclear lamina and in cytoplasmic vesicles at late times postinfection.

Authors:  Matthew S Miller; Wendy E Furlong; Leesa Pennell; Marc Geadah; Laura Hertel
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

4.  Characterization of the rhesus cytomegalovirus US28 locus.

Authors:  M E T Penfold; T L Schmidt; D J Dairaghi; P A Barry; T J Schall
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells.

Authors:  Frances M Saccoccio; Anne L Sauer; Xiaohong Cui; Amy E Armstrong; El-Sayed E Habib; David C Johnson; Brent J Ryckman; Aloysius J Klingelhutz; Stuart P Adler; Michael A McVoy
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

6.  Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells.

Authors:  G Hahn; R Jores; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

7.  Reassessing the organization of the UL42-UL43 region of the human cytomegalovirus strain AD169 genome.

Authors:  E S Mocarski; M N Prichard; C S Tan; J M Brown
Journal:  Virology       Date:  1997-12-08       Impact factor: 3.616

8.  HPV vaccines: Translating immunogenicity into efficacy.

Authors:  Taylor B Turner; Warner K Huh
Journal:  Hum Vaccin Immunother       Date:  2015-10-29       Impact factor: 3.452

9.  A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Authors:  Stuart P Adler; Anne-Marie Manganello; Ronzo Lee; Michael A McVoy; Daniel E Nixon; Stanley Plotkin; Edward Mocarski; Josephine H Cox; Patricia E Fast; Pavlo A Nesterenko; Susan E Murray; Ann B Hill; George Kemble
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.